Vimarsana
Biggest News Aggregation in the World

Sparx Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sparx Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sparx Group Today - Breaking & Trending Today

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs - Vimarsana News

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

/PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been...

Top investors share the toughest lessons they had to learn - Vimarsana News

Top investors share the toughest lessons they had to learn

No one gets good at financial decision-making without taking the risk of being wrong and then figuring out how to adjust.

Source: afr.com
Japanese satellite imagery startup iQPS see 120% liftoff in Tokyo debut - Vimarsana News

Japanese satellite imagery startup iQPS see 120% liftoff in Tokyo debut

TOKYO: Shares of Institute for Q-shu Pioneers of Space (iQPS) surged 120 per cent in their Tokyo growth-market debut on Wednesday, after the satellite imagery startup raised ¥3.48 billion (US$24 million) in an initial public offering (IPO). The stock op

Japanese satellite imagery startup iQPS surges 82% in Tokyo debut - Vimarsana News

Japanese satellite imagery startup iQPS surges 82% in Tokyo debut

International Business News: Shares of the Institute for Q-shu Pioneers of Space (iQPS) experienced an 82% surge during their Tokyo growth-market introduction on Wednesday, subseq

Arovella Therapeutics to fully focus on lead cancer programs on terminating DKK1 licence - Vimarsana News

Arovella Therapeutics to fully focus on lead cancer programs on terminating DKK1 licence

Following a strategic review of its pipeline, Arovella Therapeutics Ltd (ASX:ALA) has terminated its licence agreement with MD Anderson Cancer Centre for...